Envíos recientes

Mostrando ítems 1531-1535 de 11841

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

2022- Martínez-Cuadrón, D.; Serrano, J.; Mariz, J.; Gil, C.; Tormo, M.; [et al.]
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

2022- Labrador, J.; Martínez-Cuadrón, D.; De La Fuente, A.; Rodríguez-Veiga, R.; Serrano, J.; [et al.]
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

2023- Alvarez-Larrán, A.; Cuevas, B.; Velez, P.; Noya Pereira, María Soledad; Caballero-Navarro, G.; [et al.]
A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

2023- Mosquera Orgueira, Adrián; Díaz Arias, José; Serrano Martín, R.; Portela Piñeiro, V.; Cid López, Miguel; [et al.]